论文部分内容阅读
目的以胸部肿瘤中的非小细胞肺癌(NSCLC)为例,考察三维适形放射治疗(3DCRT)联合参芪扶正注射液治疗非小细胞肺癌(NSCLC)有效性。方法将临床NSCLC拒绝手术或失去手术治疗时机的83例患者随机分配为对照组和试验组,对照组41例,试验组42例。对患者采取3DCRT联合参芪扶正注射液治疗,放疗标准为DT(60~70)Gy/(6~7)周,参芪扶正注射液每天给予静脉滴注剂量250 ml。评价两组患者的预后状况,包括近期疗效、消化道反应、骨髓抑制以及放射性肺炎的发生率。结果全部病例病情缓解率为53%,其中对照组病情缓解率为51.2%,试验组病情缓解率54.8%;P>0.05,对照组和试验组近期疗效无显著差异;骨髓抑制、消化道反应、放射性肺炎并发率对照组分别是3例占7.3%、5例占12.2%、9例占22%和2例占4.8%、4例占9.5%和7例占16.7%,试验组显著低于对照组,P<0.05,差异有统计学意义。结论 3DCRT联合参芪扶正注射液治疗NSCLC有效,放疗毒性反应显著降低。
Objective To investigate the efficacy of three dimensional conformal radiotherapy (3DCRT) and Shenqi Fuzheng injection in the treatment of non-small cell lung cancer (NSCLC) in non-small cell lung cancer (NSCLC) in chest tumor. Methods Eighty-three patients with clinical NSCLC who refused surgery or lost surgery were randomly assigned into control group and experimental group, 41 in control group and 42 in experimental group. The patients were treated with 3DCRT combined with Shenqi Fuzheng injection. The standard of radiotherapy was DT (60 ~ 70) Gy / (6 ~ 7) weeks. Shenqi Fuzheng injection was given a daily intravenous infusion of 250 ml. The prognosis of both groups was evaluated, including recent efficacy, gastrointestinal response, bone marrow suppression, and the incidence of radiation pneumonitis. Results The disease remission rate was 53% in all cases, of which the remission rate was 51.2% in the control group and 54.8% in the experimental group; P> 0.05, there was no significant difference in the curative effect between the control group and the experimental group; the bone marrow suppression, digestive tract reaction, The incidences of radiation pneumonitis were 7.3% in 3 cases, 5 cases in 12.2%, 9 cases in 22% and 2 cases in 4.8%, 4 cases in 9.5% and 7 cases in 16.7%, and the experimental group was significantly lower than the control group Group, P <0.05, the difference was statistically significant. Conclusion 3DCRT combined with Shenqi Fuzheng injection in the treatment of NSCLC is effective, radiotherapy toxicity was significantly reduced.